Journal
NATURE REVIEWS MOLECULAR CELL BIOLOGY
Volume 11, Issue 5, Pages 329-341Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrm2882
Keywords
-
Categories
Funding
- Cancer Research UK
- Medical Research Council
- Ludwig Institute for Cancer Research
- Queen Mary University of London
- European Union [MEIF-CT-2006-039, MEIF-CT-2006-676]
- MRC [G0700755] Funding Source: UKRI
- Medical Research Council [G0700755] Funding Source: researchfish
Ask authors/readers for more resources
Phosphoinositide 3-kinases (PI3Ks) function early in intracellular signal transduction pathways and affect many biological functions. A further level of complexity derives from the existence of eight PI3K isoforms, which are divided into class I, class II and class III PI3Ks. PI3K signalling has been implicated in metabolic control, immunity, angiogenesis and cardiovascular homeostasis, and is one of the most frequently deregulated pathways in cancer. PI3K inhibitors have recently entered clinical trials in oncology. A better understanding of how the different PI3K isoforms are regulated and control signalling could uncover their roles in pathology and reveal in which disease contexts their blockade could be most beneficial.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available